rss
05-31-2019, 01:55 PM
Mini-Brain Platform Mimics Human Brain to Help Develop Drugs, Test Therapies
https://www.medgadget.com/wp-content/uploads/2019/05/mini-brains.jpg
Studying the effect of potential therapies on the human brain is exceedingly difficult. Laboratory animals have proven to be less than ideal as mimics for identifying how a given therapy will work in people, leading to exceedingly long and difficult research journeys.
Now AxoSim, a company based in New Orleans, will soon be making its Mini-Brain platform available to researchers who are studying how the brain functions, developing new drugs, and testing the toxicity of various chemicals. The technology behind the Mini-Brain has been licensed from Johns Hopkins University, where it was originally developed.
The Mini-Brain platform is a technique that provides the ability to create functional models of the human brain using induced pluripotent stem cells (iPSCs). As the iPSCs have been induced to grow into human brain-like cells, which then form the building blocks of these models, research studies employing the platform should be a lot more accurate, reproducible, and faster.
“Acquiring rights to the intellectual property underlying the Mini-Brain technology is a major step forward in our drive to transform neurology drug research,” said Lowry Curley, PhD, Chief Executive Officer of AxoSim. “Mini-Brains are live organoids that mimic multiple brain functions, allowing for a wide variety of applications in neurotoxicity and neurological diseases with the potential to substantially speed-up and increase the effectiveness of new drug R&D. The Mini-Brain technology complements our innovative Nerve-on-a-Chip platform and accelerates our strategy of providing the broadest and most scientifically robust neuroscience models to our growing roster of biopharmaceutical partners.”
Here’s a short video from AxoSim introducing its Mini-Brain platform:
Link: Mini-Brain technology info page… (https://www.axosim.com/mini-brain/)
Via: AxoSim (https://www.prnewswire.com/news-releases/axosim-licenses-revolutionary-mini-brain-technology-from-johns-hopkins-university-enabling-the-use-of-human-data-to-speed-new-drug-research-300858944.html)
http://feeds.feedburner.com/~ff/Medgadget?d=yIl2AUoC8zA (http://feeds.feedburner.com/~ff/Medgadget?a=zJA0ugzRVec:gx0JuJ45En4:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/Medgadget?d=qj6IDK7rITs (http://feeds.feedburner.com/~ff/Medgadget?a=zJA0ugzRVec:gx0JuJ45En4:qj6IDK7rITs) http://feeds.feedburner.com/~ff/Medgadget?i=zJA0ugzRVec:gx0JuJ45En4:gIN9vFwOqvQ (http://feeds.feedburner.com/~ff/Medgadget?a=zJA0ugzRVec:gx0JuJ45En4:gIN9vFwOqvQ)
http://feeds.feedburner.com/~r/Medgadget/~4/zJA0ugzRVec
https://www.medgadget.com/wp-content/uploads/2019/05/mini-brains.jpg
Studying the effect of potential therapies on the human brain is exceedingly difficult. Laboratory animals have proven to be less than ideal as mimics for identifying how a given therapy will work in people, leading to exceedingly long and difficult research journeys.
Now AxoSim, a company based in New Orleans, will soon be making its Mini-Brain platform available to researchers who are studying how the brain functions, developing new drugs, and testing the toxicity of various chemicals. The technology behind the Mini-Brain has been licensed from Johns Hopkins University, where it was originally developed.
The Mini-Brain platform is a technique that provides the ability to create functional models of the human brain using induced pluripotent stem cells (iPSCs). As the iPSCs have been induced to grow into human brain-like cells, which then form the building blocks of these models, research studies employing the platform should be a lot more accurate, reproducible, and faster.
“Acquiring rights to the intellectual property underlying the Mini-Brain technology is a major step forward in our drive to transform neurology drug research,” said Lowry Curley, PhD, Chief Executive Officer of AxoSim. “Mini-Brains are live organoids that mimic multiple brain functions, allowing for a wide variety of applications in neurotoxicity and neurological diseases with the potential to substantially speed-up and increase the effectiveness of new drug R&D. The Mini-Brain technology complements our innovative Nerve-on-a-Chip platform and accelerates our strategy of providing the broadest and most scientifically robust neuroscience models to our growing roster of biopharmaceutical partners.”
Here’s a short video from AxoSim introducing its Mini-Brain platform:
Link: Mini-Brain technology info page… (https://www.axosim.com/mini-brain/)
Via: AxoSim (https://www.prnewswire.com/news-releases/axosim-licenses-revolutionary-mini-brain-technology-from-johns-hopkins-university-enabling-the-use-of-human-data-to-speed-new-drug-research-300858944.html)
http://feeds.feedburner.com/~ff/Medgadget?d=yIl2AUoC8zA (http://feeds.feedburner.com/~ff/Medgadget?a=zJA0ugzRVec:gx0JuJ45En4:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/Medgadget?d=qj6IDK7rITs (http://feeds.feedburner.com/~ff/Medgadget?a=zJA0ugzRVec:gx0JuJ45En4:qj6IDK7rITs) http://feeds.feedburner.com/~ff/Medgadget?i=zJA0ugzRVec:gx0JuJ45En4:gIN9vFwOqvQ (http://feeds.feedburner.com/~ff/Medgadget?a=zJA0ugzRVec:gx0JuJ45En4:gIN9vFwOqvQ)
http://feeds.feedburner.com/~r/Medgadget/~4/zJA0ugzRVec